ArticleMolecular biotechnology2023
LncRNA HAGLR May Aggravate Melanoma Malignancy Via miR-4644/ASB11 Pathway.
Article in Molecular biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- A symphony of signals: the intricate role of lncRNAs in dermatological disorders.Clinical and experimental medicine · 2025Review
- Mitochondrial autophagy-related lncRNAs as prognostic biomarkers and therapeutic targets in gastric adenocarcinoma.Discover oncology · 2025Article
- Knockdown of LncRNA-HAGLR restrains the viability and motility of pancreatic cancer via miR-625-5p/TAF15 axisHeliyon · 2024Article
- Biomarker potential of competing endogenous RNA networks in Polycystic Ovary Syndrome (PCOS).Non-coding RNA research · 2024Review
- ASB1 inhibits prostate cancer progression by destabilizing CHCHD3 via K48-linked ubiquitination.American journal of cancer research · 2024Article
- Novel uveal Melanocyte cell lines display distinct features from uveal melanoma.Advances in ophthalmology practice and researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we aimed to assess the biological functions of HAGLR and its underlying mechanisms in melanoma. HAGLR and ASB11 were knocked down by transfection with the corresponding siRNAs. Meanwhile, miR-4644 was downregulated using the miR-4644 inhibitor treatment. The target interactions among the three molecules were demonstrated using dual-luciferase reporter and RNA immunoprecipitation assays. The levels of HAGLR, miR-4644, and ASB11 in melanoma cells and tissues were assessed using quantitative real‑time PCR and western blotting. The functions and mechanisms underlying HAGLR action in melanoma progression were examined using Cell Counting Kit-8, Transwell, Caspase-3 activity, and xenograft tumor formation assays. HAGLR and ASB11 expression were elevated, whereas that of miR-4644 was downregulated in melanoma cells and tissues. The viability and migration of melanoma cells (A875 and A375) were markedly suppressed by the knockdown of HAGLR and ASB11 but promoted following miR-4644 inhibitor transfection. In contrast, apoptosis showed the opposite trend. In vivo, tumor weight declined considerably with downregulation of HAGLR. Mechanistically, HAGLR sponges miR-4644, increasing the levels of ASB11 and further aggravating melanoma. It latter negatively targets ASB11 in melanoma cells. Hence, the HAGLR-miR-4644-ASB11 axis may be a promising target for melanoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.